Neurológia pre prax 1/2019
Brivaracetam (Briviact®)
New AED Briviact® described below is actually registered in EU and indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. The efficacy and safety profile of brivaracetam was established in 3 randomized, clinical trials. The most frequently reported adverse reactions with brivaracetam were somnolence and dizziness. Its main mode of action is a high and selective affinity for synaptic vesicle protein 2A. The binding affinity of brivaracetam for SV2A is twenty times higher compared with levetiracetam. The biggest benefit is that Briviact® delivers a therapeutic dose to patients from first day of use without titration.
Keywords: epilepsy, Brivaracetam, SV2A












